849470-61-7

Usage

Uses

Used in Organic Synthesis:
4-(4-Fluorophenyl)-5-formyl-6-isopropyl-2-methylsulfonylpyrimidine is used as a synthetic intermediate for the development of various organic compounds. Its unique structure allows it to be a key component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals. The presence of the formyl group, in particular, makes it a valuable precursor for further reactions, such as the formation of hydrazones, oximes, or other functionalized pyrimidines.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-(4-Fluorophenyl)-5-formyl-6-isopropyl-2-methylsulfonylpyrimidine is utilized as a building block for the creation of novel drug candidates. Its structural diversity and the ability to modify its functional groups make it suitable for the design of molecules with potential therapeutic applications. 4-(4-Fluorophenyl)-5-formyl-6-isopropyl-2-methylsulfonylpyrimidine's properties may contribute to the development of new drugs targeting a wide range of diseases and conditions.
Used in Agrochemical Development:
4-(4-Fluorophenyl)-5-formyl-6-isopropyl-2-methylsulfonylpyrimidine also finds application in the agrochemical sector, where it can be used to synthesize new pesticides, herbicides, or insecticides. Its structural features can be tailored to target specific pests or weeds, potentially leading to more effective and environmentally friendly agrochemical products.
Used in Research and Development:
In academic and industrial research settings, 4-(4-Fluorophenyl)-5-formyl-6-isopropyl-2-methylsulfonylpyrimidine serves as a valuable compound for exploring new chemical reactions and synthetic pathways. Its reactivity and the possibility of functional group manipulation make it an interesting subject for studies aimed at advancing the field of organic chemistry and its applications.

Upstream product

• 147118-28-3 ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxylate 
• 147118-27-2 ethyl 4-(4-fluorophenyl)-2-(methylsulfanyl)-6-(propan-2-yl)-pyrimidine-5-carboxylate 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 122930-45-4 (E)-2-<(4-fluorophenyl)methylene>-4-methyl-3-oxopentanoic acid ethyl ester 
• 459-57-4 4-fluorobenzaldehyde 
• 849470-59-3 (4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidin-5-yl)methanol 

Downstream Products

• 147118-24-9 (E)-(3R,5S)-7-[4-(4-Fluoro-phenyl)-6-isopropyl-2-methanesulfonyl-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid methyl ester 
• 1026025-03-5 C₃₀H₃₉FN₆O₄ 
• 849470-63-9 tert-butyl 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)-acetate 

Relevant academic research and scientific papers

Development of a scaleable process for the synthesis of a next-generation statin

This manuscript details the process research and development of a convergent and safe approach to 1 on a multikilo scale. Specific highlights of the process development efforts will be described, including the development of a dehydrogenation method for d

(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2, 4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): A rationally designed orally efficacious 3-hydroxy-3- methylglutaryl coenzyme-A reductase inhibitor wi

3-Hydroxy-3-methylglutaryl coenzyme-A reductase (HMGR) inhibitors, more commonly known as statins, represent the gold standard in treating hypercholesterolemia. Although statins are regarded as generally safe, they are known to cause myopathy and, in rare

PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL AS HMG-COA REDUCTASE INHIBITORS AND METHOD OF PREPARATION THEREOF

Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol

Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors

A novel series of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates were synthesized and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Monocalcium bis(+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methanesulfonylaminopyrimidin)-5-yl]-(3R,5S)-dihydroxy- (E)-6-heptenoate (3a, S-4522) was selected as a candidate for further evaluation. Compound 3a was approximately four times more potent than lovastatin sodium salt (in inhibiting HMG-CoA reductase in vitro (IC50 = 11 nM). Compound 3a was shown to be the most potent cholesterol biosynthesis inhibitor in this series (IC50 = 1.12 nM) in rat isolated hepatocytes; its inhibitory activity was approximately 100 times more potent than pravastatin.